Stock analysts at Janney Montgomery Scott began coverage on shares of ProQR Therapeutics NV (NASDAQ:PRQR) in a research report issued on Wednesday, The Fly reports. The firm set a “neutral” rating on the biopharmaceutical company’s stock.
Other analysts have also recently issued reports about the stock. Leerink Swann reaffirmed a “buy” rating on shares of ProQR Therapeutics NV in a research report on Thursday, August 18th. JMP Securities reaffirmed a “buy” rating on shares of ProQR Therapeutics NV in a research report on Tuesday, September 6th. Zacks Investment Research raised shares of ProQR Therapeutics NV from a “sell” rating to a “hold” rating in a research report on Friday, September 23rd. Finally, Chardan Capital started coverage on shares of ProQR Therapeutics NV in a research report on Monday, June 20th. They set a “neutral” rating and a $4.50 price target for the company. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. ProQR Therapeutics NV currently has a consensus rating of “Buy” and a consensus target price of $15.94.
Shares of ProQR Therapeutics NV (NASDAQ:PRQR) opened at 6.75 on Wednesday. ProQR Therapeutics NV has a 52-week low of $3.48 and a 52-week high of $16.23. The stock’s 50 day moving average price is $5.97 and its 200-day moving average price is $5.22. The firm’s market cap is $157.59 million.
ProQR Therapeutics NV (NASDAQ:PRQR) last announced its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.00. On average, equities research analysts anticipate that ProQR Therapeutics NV will post ($2.14) earnings per share for the current fiscal year.
An institutional investor recently raised its position in ProQR Therapeutics NV stock. Redmile Group LLC boosted its position in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 5.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 581,638 shares of the biopharmaceutical company’s stock after buying an additional 28,925 shares during the period. Redmile Group LLC owned approximately 2.49% of ProQR Therapeutics NV worth $2,815,000 at the end of the most recent quarter. 39.21% of the stock is owned by institutional investors and hedge funds.
ProQR Therapeutics NV Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related companies with MarketBeat.com's FREE daily email newsletter.